Anti-MASP-2 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody targeting MASP-2 (mannan-binding lectin serine protease 2), validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Mouse, Rat, Pan
UniProt
O00187
Size
100ug
Cat. #
RP1MASP2

In stock

SKU
RP-MASP2

Options

As low as: $130.00

Target Overview

Mannan-binding lectin serine protease 2 (MASP-2, EC 3.4.21.104, UniProt O00187) is a 686-amino acid secreted serine protease that activates the lectin pathway of the complement system. MASP-2 circulates as a zymogen and is cleaved by MASP-1 following association of pattern-recognition lectins (MBL2, ficolins FCN1/2/3) with carbohydrate structures on pathogen surfaces. Once activated, MASP-2 functions as a C4/C2 convertase, cleaving complement components C4 and C2 to generate the C3 convertase and propagate the complement cascade. This leads to opsonization, formation of the membrane attack complex, and inflammatory signaling that bridges innate and adaptive immunity. MASP-2 also exhibits procoagulant activity through direct cleavage of prothrombin to thrombin. The protein is synthesized primarily in hepatocytes and circulates in complex with mannose-binding lectin and ficolins. Researchers study MASP-2 in the context of infectious disease, autoimmunity (particularly lupus nephritis), transplant rejection, and thrombotic disorders, where lectin pathway dysregulation contributes to pathology.

Background

The lectin complement pathway represents one of three major routes of complement activation, distinguished by its reliance on carbohydrate pattern recognition rather than antibody or spontaneous hydrolysis. MASP-2 serves as the essential effector protease of this pathway, performing a role analogous to C1s in the classical pathway. Following pathogen recognition by soluble lectins, MASP-1 initiates a proteolytic cascade by cleaving and activating MASP-2, which then cleaves C4 into C4a and C4b, and C2 into C2a and C2b, forming the C3 convertase C4b2a. This mechanism has been validated across multiple experimental systems and is central to host defense against encapsulated bacteria and certain viruses. Beyond its canonical complement role, recent work has demonstrated that MASP-2 can directly convert prothrombin to thrombin, establishing a molecular link between complement activation and coagulation. MASP-2 has emerged as a therapeutic target in complement-mediated diseases. Narsoplimab, a human monoclonal antibody inhibitor of MASP-2, received regulatory approval for hematopoietic stem cell transplant-associated thrombotic microangiopathy, validating the clinical relevance of lectin pathway inhibition. Preclinical studies continue to explore MASP-2 blockade in lupus nephritis, where bispecific antibodies targeting both MASP-2 and MASP-3 have shown superior renoprotective effects compared to monotherapy in murine models. Lindelöf et al. (2026) identified MAP-1, a splice variant of MASP-2 lacking protease activity, as a biomarker associated with hematological manifestations and elevated type I interferon activity in systemic lupus erythematosus patients. The lectin pathway also functions in mucosal immunity, with evidence that probiotic bacteria modulate MASP-2 activity as part of epithelial barrier defense mechanisms. Five domain-specific rabbit polyclonal antibodies targeting different regions of MASP-2 are available for researchers investigating lectin pathway biology, complement regulation, and associated pathologies.

References

  1. Lindelöf L et al (2026) Lectin pathway of complement in SLE: MAP-1 as a marker of haematological manifestations and elevated type I interferon activity. Lupus Sci Med. PubMed · DOI
  2. Tu T et al (2026) Bispecific MASP-2/3 antibody provides superior renoprotection over monotherapy in pristane-induced lupus nephritis. Clin Exp Immunol. PubMed · DOI
  3. Shirley M (2026) Narsoplimab: First Approval. Drugs. PubMed · DOI
  4. Gao X et al (2026) Lactobacillus rhamnosus confers protection against enteropathogenic bacteria by enhancing mucosal immunity and epithelial barrier function. Front Cell Infect Microbiol. PubMed · DOI
  5. Nakahara M et al (2026) Functional evidence for the existence of a bona-fide C2 component in teleost complement system. Dev Comp Immunol. PubMed · DOI

Additional Specifications

Gene Symbol MASP2
UniProt ID O00187
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Mouse, Rat, Pan
Pack Size 100ug
Immunogen (Cub Domain #1)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 16-137.
Immunogen (Cub Domain/EGF-like domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 16-137.
Immunogen (Second Cub Domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 184-296.
Immunogen (Hinge region)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 554-574.
Immunogen (Carboxyterminal end)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 636-686.
Alternate Names MASP-2, Mannan-binding lectin serine protease 2, MBL-associated serine protease 2, Mannose-binding protein-associated serine protease 2, EC 3.4.21.104, MAP19, MASP2

Frequently Asked Questions

What molecular weight band should I expect for MASP-2 on Western blot?

Full-length MASP-2 runs at approximately 76 kDa under reducing conditions, corresponding to the uncleaved zymogen form most abundant in serum and cell lysates. Upon activation, MASP-2 is cleaved into a heavy chain (approximately 55 kDa) and a light chain (approximately 27 kDa) that remain disulfide-linked. Under non-reducing conditions, you may observe the 76 kDa form plus higher-molecular-weight complexes if MASP-2 is associated with MBL or ficolins. The antibody recognizes the zymogen; confirm epitope location if you need to detect specific cleaved fragments.

What is the recommended starting dilution for MASP-2 Western blot?

Start at 1:1000 dilution in blocking buffer for Western blot of human serum or liver lysate, which express MASP-2 at physiologically relevant levels. MASP-2 circulates at approximately 400-500 ng/mL in normal human serum, so load at least 5-10 µg total serum protein per lane for reliable detection. For recombinant MASP-2 or overexpression lysates, you may titrate up to 1:2000. Hepatocyte or HepG2 lysates typically require the 1:1000 starting point. Optimize exposure time before adjusting dilution, as MASP-2 is not a high-abundance target in most samples.

Does this antibody cross-react with mouse or rat MASP-2?

Human MASP-2 shares approximately 80% sequence identity with mouse and 78% with rat orthologs, primarily in the serine protease and CUB domains. Cross-reactivity is predicted but not yet validated in our hands. If working with rodent samples, run a positive control (recombinant mouse MASP-2 or mouse serum known to contain MASP-2) alongside your experimental samples. Expect the band near 75-76 kDa. Some polyclonal antibodies raised against human MASP-2 do recognize rodent forms; empirical testing is required to confirm performance in your system.

What sample types and lysis buffers work best for detecting endogenous MASP-2?

MASP-2 is a secreted protein, so serum, plasma, and conditioned media from hepatocytes are the richest sources. For tissue lysates, liver expresses the highest levels. Use RIPA or NP-40-based lysis buffers with protease inhibitors; avoid high concentrations of reducing agents during lysis if you wish to preserve MASP-2 complexes with MBL or ficolins. EDTA in sample buffer will dissociate calcium-dependent lectin interactions. For cell lysates, HepG2 or primary hepatocytes are suitable models. MASP-2 is not abundant in most non-hepatic cell lines, so consider spiking recombinant protein as a positive control.

Can this antibody distinguish between MASP-2 isoforms or splice variants?

Human MASP-2 has two main isoforms: the full-length form (686 amino acids, NM_006610) and a shorter splice variant called MAP19 or sMAP (formerly called small MBL-associated protein), which lacks the serine protease domain and functions as a competitive inhibitor. Without epitope mapping data, assume this polyclonal antibody was raised against a region present in full-length MASP-2. If MAP19 shares that epitope, you may detect a band near 19 kDa. Run recombinant MAP19 as a control if distinguishing isoforms is critical to your experiment.

What controls should I include when using this MASP-2 antibody for the first time?

Include normal human serum (5-10 µg protein per lane) as a positive control; MASP-2 circulates constitutively. Recombinant human MASP-2 (if available) provides a defined-MW reference. For a negative control, use serum or lysate from a cell type that does not express MASP-2, or pre-incubate the antibody with blocking peptide if supplied. Consider a no-primary-antibody lane to assess non-specific secondary binding. If studying lectin-pathway activation, include a sample treated with a known MASP-2 inhibitor to confirm specificity of any cleavage or activity-dependent signal.

How should I store the MASP-2 antibody and what is the expected shelf life?

Store the antibody at -20°C in single-use aliquots to avoid freeze-thaw cycles, which can reduce titre and increase aggregation. Polyclonal antibodies in glycerol-containing storage buffer typically remain stable for 12-24 months at -20°C. For short-term use (up to one month), an aliquot may be held at 4°C with sodium azide preservative. Do not store diluted antibody; prepare working dilutions fresh for each experiment. If you observe elevated background or loss of signal over time, thaw a fresh aliquot and compare side-by-side before troubleshooting other variables.

Will this antibody detect MASP-2 in immunohistochemistry or immunofluorescence?

This antibody is validated for Western blot; IHC and immunofluorescence validation is in progress across the TPB catalogue, but confirm protocol compatibility for MASP-2 specifically. For IHC on formalin-fixed paraffin-embedded liver sections, antigen retrieval (citrate buffer, pH 6.0, heat-induced) is typically required. MASP-2 localizes primarily to hepatocyte cytoplasm and is secreted, so extracellular staining may be faint unless tissue was perfused to retain serum. Start at 1:100 to 1:200 dilution for IHC. For IF on cultured hepatocytes, fix with 4% paraformaldehyde and permeabilize with 0.1% Triton X-100.

Western blot validation for RP-MASP2 — 4 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

MASP-2: Cub Domain/EGF-like domain — WB validation
WB · Panel 1 MASP-2: Cub Domain/EGF-like domain
MASP-2: Second Cub Domain — WB validation
WB · Panel 2 MASP-2: Second Cub Domain
MASP-2: Hinge region — WB validation
WB · Panel 3 MASP-2: Hinge region
MASP-2: Carboxyterminal end — WB validation
WB · Panel 4 MASP-2: Carboxyterminal end

Custom validation studies available on request — contact us.

Also known as:

  • MASP-2
  • Mannan-binding lectin serine protease 2
  • MBL-associated serine protease 2
  • Mannose-binding protein-associated serine protease 2
  • EC 3.4.21.104
  • MAP19
  • MASP2
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →